A new study using machine learning is the first of its kind to comprehensively characterize how proteoglycans play a role in breast cancer prognosis and tumor aggressiveness.

The Calibr-Skaggs Institute for Innovative Medicines, the drug development division of Scripps Research, today announced a milestone in cancer treatment with the dosing of the first patient in a phase 1 trial (NCT06878248) evaluating CLBR001 + ABBV-461, a modular, switchable chimeric antigen receptor T cell (sCAR-T) therapy in patients with advanced or metastatic breast cancer who have no suitable treatment options. This is the first study of the sCAR-T platform in solid tumors.

A new gene-editing method enables researchers to more easily determine whether a patient has inherited an increased risk of developing cancer - before any symptoms appear. Researchers at Rigshospitalet in Copenhagen have tested the method in a hospital setting and believe it has the potential to save lives worldwide.

Researchers from the University of São Paulo have identified a molecule in arachnid venom that acts similarly to a commonly used chemotherapy drug for treating the disease; preliminary results of the study were presented at FAPESP Week France.

Lead author Claire Morton, MD, and senior author Christina Ahn Minami, MD, MS, both of the Department of Surgery at Brigham and Women’s Hospital, published a paper in Current Breast Cancer Reports “Survivorship Issues in Older Adults with Breast Cancer